Early Knee Osseous Arthrophlogosis
Conditions
Brief summary
This study collected general data from 90 patients with KOA in the outpatients and ward of Henan Provincial People's Hospital from January 2023 to December 2023 to compare the long-term effects of intra-articular PRP combined with acupoint PRP, intra-articular PRP, and intra-articular HA on symptoms in patients with mild to moderate osteoarthritis
Interventions
OTHERPRP joint injection combined with acupoint injection
PRP acupoint injection
Sponsors
Zhengzhou Revo-Gene Technology Co., LTD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Intervention model description
90 subjects were randomly divided into three groups, with 30 cases in each group. (1) HA group: The patients were given intraarticular injection of sodium hyaluronate injection, 2ml each time, and normal saline injection of 1ml at Xuehai point, Yanglingquan point and Wezhong point, once a week for 4 weeks. (2) PRP joint cavity injection group: PRP knee cavity injection was given, 3.5ml each time, and normal saline injection was given at Xuechai point, Yanglingquan point and Weizhong point 1ml, once a week for 4 weeks; (3) PRP joint cavity combined with acupoint injection group: PRP was given intraventricular injection of knee joint, each injection was 3.5ml, while PRP was given 1ml injection of Xuehai point, Yanglingquan point and Weizhong point, once a week for 4 weeks.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. The expected survival period is more than 3 months; 2. The clinical diagnosis was early knee osteoarthritis; 3. Capable of knee injections; 4. chronic joint pain or swelling (\> 4 months); 5. It meets the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Osteoarthritis (2021 Edition) , and the X-ray evaluation results meet the Kellgren-Lawrence scale (K-L scale) level I to level III.
Exclusion criteria
1. age over 80 years old; 2. K-L classification is greater than Ⅲ grade; 3. Combined with rheumatoid arthritis, severe osteoporosis, tumor, gout, obvious joint deformity and other diseases; 4. Poor compliance, not according to the provisions of treatment; 5. Pregnant and lactating women; 6. Patients voluntarily withdrew from the study; 7. Patients were lost to follow-up due to various reasons during follow-up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analog Scale (VAS) score | Assessments will be conducted at weeks 1, 3, 6, and 12 after treatment. | Visual Analog Scale (VAS) score ranging from 1 to 10, with lower scores indicating less pain intensity |
| Knee Society Score (KSS) | Assessments will be conducted at weeks 1, 3, 6, and 12 after treatment. | Knee Society Score (KSS), which consists of five major items totaling 200 points. Higher scores indicate better knee joint function |
| Western Ontario and McMaster Universities Osteoarthritis Index | Assessments will be conducted at 1, 3, 6, and 12 months after treatment. | The severity of knee osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, consisting of 24 items with a total possible score of 240 points. Lower WOMAC scores indicate less severe knee osteoarthritis. |
Countries
China
Outcome results
None listed